Showing results (151-160 of 258) with videos related to

Sort By:
Pageof 26
Plos One|November 14, 2013
EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutationTeppei Yamada, Koichi Azuma, Emi Muta, et al.
Journal of Gastroenterology|December 4, 2016
NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1bEiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 18, 2005
Body surface area is an independent factor contributing to the effects of lamivudine treatmentMakoto Nakamuta, Kazuhiro Kotoh, Yuichi Tanabe, et al.
Internal Medicine (Tokyo, Japan)|November 20, 2010
Elevated levels of thioredoxin 1 in the lungs and sera of idiopathic pulmonary fibrosis, non-specific interstitial pneumonia and cryptogenic organizing pneumoniaYasuhiro Iwata, Masaki Okamoto, Tomoaki Hoshino, et al.
Antiviral Research|October 10, 2018
Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney diseaseEiichi Ogawa, Norihiro Furusyo, Koichi Azuma, et al.
Frontiers in Immunology|October 20, 2025
Machine learning-based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitorsFeifei Wei, Hiroyuki Takeda, Koichi Azuma, et al.
Cancer Science|September 21, 2025
Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC TrialYoshitaka Zenke, Yoshimasa Shiraishi, Yasushi Goto, et al.
Journal for Immunotherapy of Cancer|May 15, 2022
Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate modelKoichi Azuma, Huihui Xiang, Tomoyuki Tagami, et al.
BMJ Open|June 22, 2019
Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in JapanAtaru Igarashi, Norihiro Furusyo, Eiichi Ogawa, et al.
ESMO Open|November 16, 2016
Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinibKoichi Azuma, Tomonori Hirashima, Nobuyuki Yamamoto, et al.
Pageof 26